论文信息 - The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. - 字舞流文

The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.

M. Bauckneht | E. Seregni | A. Lorenzoni | S. Pusceddu | G. Aliberti | F. Scalorbi | G. Argiroffi | S. Mazzaglia | Mariarosaria Cuomo | Calareso Giuseppina | Carlo Chiesa | Matteo Bagnalasta | Marco Maccauro | Margarita Kirienko | Garanzini Enrico Matteo